A Phase 2 Open-Label Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
S
Sara Grethlein, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.
Detailed description of study
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Squamous Cell Carcinoma
-
Age: 18 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1707237874 (MK-3475-629)
